Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 - 2018
Standard
Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 - 2018. / Guggenbühl Noller, Jessica Michelle; Froeschl, Guenter; Eisermann, Philip; Jochum, Johannes; Theuring, Stefanie; Reiter-Owona, Ingrid; Bissinger, Alfred Lennart; Hoelscher, Michael; Bakuli, Abhishek; von Sonnenburg, Franz-Josef Falkner; Rothe, Camilla; Bretzel, Gisela; Albajar-Viñas, Pedro; Grout, Lise; Pritsch, Michael.
in: BMC INFECT DIS, Jahrgang 20, Nr. 1, 03.12.2020, S. 919.Publikationen: SCORING: Beitrag in Fachzeitschrift/Zeitung › SCORING: Zeitschriftenaufsatz › Forschung › Begutachtung
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - Describing nearly two decades of Chagas disease in Germany and the lessons learned: a retrospective study on screening, detection, diagnosis, and treatment of Trypanosoma cruzi infection from 2000 - 2018
AU - Guggenbühl Noller, Jessica Michelle
AU - Froeschl, Guenter
AU - Eisermann, Philip
AU - Jochum, Johannes
AU - Theuring, Stefanie
AU - Reiter-Owona, Ingrid
AU - Bissinger, Alfred Lennart
AU - Hoelscher, Michael
AU - Bakuli, Abhishek
AU - von Sonnenburg, Franz-Josef Falkner
AU - Rothe, Camilla
AU - Bretzel, Gisela
AU - Albajar-Viñas, Pedro
AU - Grout, Lise
AU - Pritsch, Michael
PY - 2020/12/3
Y1 - 2020/12/3
N2 - BACKGROUND: The highly complex and largely neglected Chagas disease (CD) has become a global health problem due to population movements between Latin America and non-endemic countries, as well as non-vectorial transmission routes. Data on CD testing and treatment from routine patient care in Germany of almost two decades was collected and analysed.METHODS: German laboratories offering diagnostics for chronic Trypanosoma cruzi (T. cruzi) infection in routine patient care were identified. All retrievable data on tests performed during the years of 2000-2018 were analysed. Additional clinical information regarding patients diagnosed with CD was collected through questionnaires.RESULTS: Five German laboratories with diagnostics for T. cruzi infection in routine patient care were identified. Centres in Hamburg and Munich offered two independent serological tests to confirm the CD diagnosis, as recommended by WHO during the entire time period 2000-2018. Overall, a total of n = 10,728 independent tests involving n = 5991 individuals were identified with a progressive increase in testing rates over time, only n = 130 (16.0%) of the tested individuals with known nationality came from CD endemic countries. Of all test units conducted at the included institutes, a total of n = 347/10,728 (3.2%) tests on CD were positive, of which n = 200/347 (57.6%) were ELISA, n = 133/347 (38.3%) IFT, n = 10/347 (2.9%) PCR, and n = 4/347 (1.2%) RDT. Of the n = 5991 individuals only n = 81 (1.4%) with chronic infection were identified, n = 52 females and n = 28 males. Additional clinical information could only be collected from n = 47.CONCLUSION: The results of this study give insight into the deployment of screening, detection, diagnosis, and treatment of T. cruzi over the last two decades in Germany and existing deficits therein; the creation of guidelines for Germany could be a step forward to improve the existing gaps.
AB - BACKGROUND: The highly complex and largely neglected Chagas disease (CD) has become a global health problem due to population movements between Latin America and non-endemic countries, as well as non-vectorial transmission routes. Data on CD testing and treatment from routine patient care in Germany of almost two decades was collected and analysed.METHODS: German laboratories offering diagnostics for chronic Trypanosoma cruzi (T. cruzi) infection in routine patient care were identified. All retrievable data on tests performed during the years of 2000-2018 were analysed. Additional clinical information regarding patients diagnosed with CD was collected through questionnaires.RESULTS: Five German laboratories with diagnostics for T. cruzi infection in routine patient care were identified. Centres in Hamburg and Munich offered two independent serological tests to confirm the CD diagnosis, as recommended by WHO during the entire time period 2000-2018. Overall, a total of n = 10,728 independent tests involving n = 5991 individuals were identified with a progressive increase in testing rates over time, only n = 130 (16.0%) of the tested individuals with known nationality came from CD endemic countries. Of all test units conducted at the included institutes, a total of n = 347/10,728 (3.2%) tests on CD were positive, of which n = 200/347 (57.6%) were ELISA, n = 133/347 (38.3%) IFT, n = 10/347 (2.9%) PCR, and n = 4/347 (1.2%) RDT. Of the n = 5991 individuals only n = 81 (1.4%) with chronic infection were identified, n = 52 females and n = 28 males. Additional clinical information could only be collected from n = 47.CONCLUSION: The results of this study give insight into the deployment of screening, detection, diagnosis, and treatment of T. cruzi over the last two decades in Germany and existing deficits therein; the creation of guidelines for Germany could be a step forward to improve the existing gaps.
KW - Adolescent
KW - Adult
KW - Chagas Disease/diagnosis
KW - Diagnostic Tests, Routine/methods
KW - Emigrants and Immigrants
KW - Enzyme-Linked Immunosorbent Assay
KW - Female
KW - Follow-Up Studies
KW - Germany/epidemiology
KW - Humans
KW - Male
KW - Mass Screening/methods
KW - Middle Aged
KW - Neglected Diseases/epidemiology
KW - Polymerase Chain Reaction
KW - Retrospective Studies
KW - Serologic Tests
KW - Trypanosoma cruzi/genetics
KW - Young Adult
U2 - 10.1186/s12879-020-05600-8
DO - 10.1186/s12879-020-05600-8
M3 - SCORING: Journal article
C2 - 33272201
VL - 20
SP - 919
JO - BMC INFECT DIS
JF - BMC INFECT DIS
SN - 1471-2334
IS - 1
ER -
